Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dichloroquine is a non-specific term used in pharmaceutical and toxicological literature to refer to several distinct chlorinated quinoline derivatives. Most commonly, in historical medical contexts such as the study of Subacute Myelo-Optico-Neuropathy (S.M.O.N.), it refers to **5,7-dichloro-8-quinolinol** (INN: **chlorquinaldol**), a halogenated hydroxyquinoline with antibacterial and antifungal properties used primarily for skin infections. In the field of antimalarial research, the term is often used as a shorthand for **4,7-dichloroquinoline**, a critical chemical intermediate in the synthesis of 4-aminoquinoline drugs like chloroquine. Additionally, the name has been applied to novel experimental derivatives, such as the heme-binding compound **CQ-D2**, which are investigated for their ability to prevent oxidative damage in hemoglobinopathies like beta-thalassemia or to enhance curative outcomes in cerebral malaria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dichloroquine.